Back
 OJU  Vol.2 No.2 , May 2012
Clinico-Pathological Characterization of Hereditary, Familial and Sporadic Prostate Cancer
Abstract: Aim: To characterize familial prostate cancer including hereditary prostate cancer and assess the disease-free survival following radical prostatectomy. Methods: A self-administered written questionnaire was forwarded to 709 prostatectomized patients from the Aarhus Prostate Cancer Study containing questions about cases of prostate cancer (PC), age at diagnosis, vital status, and age at death for all first-degree relatives. Patients were then divided into groups according to their family history: hereditary prostate cancer (HPC), familial prostate cancer (FPC), and sporadic prostate cancer (SPC) groups. The information from a subset of both FPC (n = 17) and SPC (n = 17) groups were validated in the Danish Cancer Register and the Civil Registration System. Between groups, we described the association of age, prostatespecific antigen (PSA), postoperative Gleason score and T Stage. A Kaplan-Meier curve demonstrated postoperative disease-free survival in each group. Results: The response rate was 81% (574/709). About 21% of the patients were categorized in the FPC group, of which 7% were identified as having HPC. The median follow-up time was 63 months for HPC, 65 months for FPC and 88 months for SPC. Overall, there was no significant difference between groups in clinical features and disease-free survival except that patients with HPC were significantly associated with younger age than sporadic cases (p = 0.02). The proportion of self-reported PC diagnoses confirmed in the cancer register was 27.8%. The index persons with SPC reported no PC in first-degree relatives and none was found the cancer register. Conclusion: Overall, we found no difference in clinical characteristics and survival, following radical prostatectomy except that patients with HPC were younger at diagnosis. These results are in line with previously reported data.
Cite this paper: D. Nguyen Bentzon, A. Sofie Lynnerup and M. Borre, "Clinico-Pathological Characterization of Hereditary, Familial and Sporadic Prostate Cancer," Open Journal of Urology, Vol. 2 No. 2, 2012, pp. 38-44. doi: 10.4236/oju.2012.22008.
References

[1]   J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers and D. M. Parkin, “Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer, Vol. 127, No. 12, 2010, pp. 2893-2917. doi:10.1002/ijc.25516

[2]   A. Jemal, M. M. Center, C. DeSantis and E. M. Ward, “Global Patterns of Cancer Incidence and Mortality Rates and Trends,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 19, 2010, pp. 1893-1907. doi:10.1158/1055-9965.EPI-10-0437

[3]   Sundhedsstyrelsen, “Cancerregisteret,” 2009.

[4]   M. P. Zeegers, A. Jellema and H. Ostrer, “Empiric Risk of Prostate Carcinoma for Relatives of Patients with Prostate Carcinoma: A Meta-Analysis,” Cancer, Vol. 97, No. 8, 2003, pp. 1894-1903. doi:10.1002/cncr.11262

[5]   B. S. Carter, G. S. Bova, T. H. Beaty, et al., “Hereditary Prostate Cancer: Epidemiologic and Clinical Features,” The Journal of Urology, Vol. 150, No. 3, 1993, pp. 797-802.

[6]   W. F. Page, M. M. Braun, A. W. Partin, N. Caporaso and P. Walsh, “Heredity and Prostate Cancer: A Study of World War II Veteran Twins,” The Prostate, Vol. 33, No. 4, 1997, pp. 240-245. doi:10.1002/(SICI)1097-0045(19971201)33:4<240::AID-PROS3>3.0.CO;2-L

[7]   P. Lichtenstein, N. V. Holm, P. K. Verkasalo, et al., “Environmental and Heritable Factors in the Causation of Cancer—Analyses of Cohorts of Twins from Sweden, Denmark, and Finland,” The New England Journal of Medicine, Vol. 343, No. 2, 2000, pp. 78-85. doi:10.1056/NEJM200007133430201

[8]   S. G. Baker and B. S. Kramer, “Using Microarrays to Study the Microenvironment in Tumor Biology: The Crucial Role of Statistics,” Seminars in Cancer Biology, Vol. 18, No. 5, 2008, pp. 305-310. doi:10.1016/j.semcancer.2008.03.001

[9]   O. Bratt, U. Kristoffersson, H. Olsson and R. Lundgren, “Clinical Course of Early Onset Prostate Cancer with Special Reference to Family History as a Prognostic Factor,” European Urology, Vol. 34, No. 1, 1998, pp. 19-24.

[10]   O. Bratt, J. E. Damber, M. Emanuelsson and H. Gronberg, “Hereditary Prostate Cancer: Clinical Characteristics and Survival,” The Journal of Urology, Vol. 167, No. 6, 2002, pp. 2423-2426. doi:10.1016/S0022-5347(05)64997-X

[11]   H. H. Storm, “Completeness of Cancer Registration in Denmark 1943-1966 and Efficacy of Record Linkage Procedures,” International Journal of Epidemiology, Vol. 17, No. 1, 1988, pp. 44-49. doi:10.1093/ije/17.1.44

[12]   Osterlind and O. M. Jensen, “Evaluation of Cancer Registration in Denmark in 1977. Preliminary Evaluation of Cancer Registration by the Cancer Register and the National Patient Register,” Ugeskrift for Laeger, Vol. 147, No. 31, 1985, pp. 2483-2488.

[13]   V. D’Amico, R. Whittington, S. B. Malkowicz, et al., “Biochemical Outcome after Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer,” The Journal of the American Medical Association, Vol. 280, No. 11, 1998, pp. 969-974. doi:10.1001/jama.280.11.969

[14]   Y. C. Chen, J. H. Page, R. Chen and E. Giovannucci, “Family History of Prostate and Breast Cancer and the Risk of Prostate Cancer in the PSA Era,” The Prostate, Vol. 68, No. 14, 2008, pp. 1582-1591. doi:10.1002/pros.20825

[15]   B. S. Carter, T. H. Beaty, G. D. Steinberg, B. Childs and P. C. Walsh, “Mendelian Inheritance of Familial Prostate Cancer,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 89, No. 8, 1992, pp. 3367-3371. doi:10.1073/pnas.89.8.3367

[16]   E. Sacco, T. Prayer-Galetti, F. Pinto, et al., “Familial and Hereditary Prostate Cancer by Definition in an Italian Surgical Series: Clinical Features and Outcome,” European Urology, Vol. 47, No. 6, 2005, pp. 761-768. doi:10.1016/j.eururo.2005.01.016

[17]   H. Gronberg, L. Damber, B. Tavelin and J. E. Damber, “No Difference in Survival between Sporadic, Familial and Hereditary Prostate Cancer,” British Journal of Urology, Vol. 82, No. 4, 1998, pp. 564-567. doi:10.1046/j.1464-410X.1998.00801.x

[18]   A. Valeri, R.Azzouzi, E. Drelon, et al., “Early-Onset Hereditary Prostate Cancer Is Not Associated with Specific Clinical and Biological Features,” The Prostate, Vol. 45, No. 1, 2000, pp. 66-71. doi:10.1002/1097-0045(20000915)45:1<66::AID-PROS8>3.0.CO;2-W

[19]   K. A. Roehl, S. Loeb, J. A. Antenor, N. Corbin and W. J. Catalona, “Characteristics of Patients with Familial versus Sporadic Prostate Cancer,” The Journal of Urology, Vol. 176, No. 6, 2006, pp. 2438-2342. doi:10.1016/j.juro.2006.07.159

[20]   D. W. Keetch, P. A. Humphrey, D. S. Smith, D. Stahl and W. J. Catalona, “Clinical and Pathological Features of Hereditary Prostate Cancer,” The Journal of Urology, Vol. 155, No. 6, 1996, pp. 1841-1843. doi:10.1016/S0022-5347(01)66024-5

[21]   S. I. Bastacky, K. J. Wojno, P. C. Walsh, M. J. Carmichael and J. I. Epstein, “Pathological Features of Hereditary Prostate Cancer,” The Journal of Urology, Vol. 153, No. 3, 1995, pp. 987-992. doi:10.1016/S0022-5347(01)67619-5

[22]   H. Gronberg, J. Xu, J. R. Smith, et al., “Early Age at Diagnosis in Families Providing Evidence of Linkage to the Hereditary Prostate Cancer Locus (HPC1) on Chromosome 1,” Cancer Research, Vol. 57, No. 21, 1997, pp. 4707-4709

[23]   H. Gronberg, S. D. Isaacs, J. R. Smith, et al., “Characteristics of Prostate Cancer in Families Potentially Linked to the Hereditary Prostate Cancer 1 (HPC1) Locus,” The Journal of the American Medical Association, Vol. 278, No. 15, 1997, pp. 1251-1255. doi:10.1001/jama.1997.03550150055035

[24]   E. L. Goode, J. L. Stanford, M. A. Peters, et al., “Clinical Characteristics of Prostate Cancer in an Analysis of Linkage to Four Putative Susceptibility Loci,” Clinical Cancer Research, Vol. 7, No. 9, 2001, pp. 2739-2749

[25]   P. A. Kupelian, V. A. Kupelian, J. S. Witte, R. Macklis and E. A. Klein, “Family History of Prostate Cancer in Patients with Localized Prostate Cancer: An Independent Predictor of Treatment Outcome,” Journal of Clinical Oncology, Vol. 15, No. 4, 1997, pp. 1478-1480.

[26]   J. J. Bauer, S. Srivastava, R. R. Connelly, et al., “Significance of Familial History of Prostate Cancer to Traditional Prognostic Variables, Genetic Biomarkers, and Recurrence after Radical Prostatectomy,” Urology, Vol. 51, No. 6, 1998, pp. 970-976. doi:10.1016/S0090-4295(98)00103-4

[27]   G. S. Bova, A. W. Partin, S. D. Isaacs, et al., “Biological Aggressiveness of Hereditary Prostate Cancer: Long-Term Evaluation Following Radical Prostatectomy,” The Journal of urology, Vol. 160, No. 3, 1998, pp. 660-663. doi:10.1016/S0022-5347(01)62748-4

[28]   O. Bratt, U. Kristoffersson, R. Lundgren and H. Olsson, “Familial and Hereditary Prostate Cancer in Southern Sweden. A Population-Based Case-Control Study,” European Journal of Cancer, Vol. 35, No. 2, 1999, pp. 272-277.

[29]   T. M. King, L. Tong, R. J. Pack, C. Spencer and C. I. Amos, “Accuracy of Family History of Cancer as Reported by Men with Prostate Cancer,” Urology, Vol. 59, No. 4, 2002, pp. 546-550. doi:10.1016/S0090-4295(01)01598-9

[30]   G. H. Rauscher and D. P. Sandler, “Validating Cancer Histories in Deceased Relatives,” Epidemiology, Vol. 16, No. 2, 2005, pp. 262-265.

 
 
Top